New Zealand's disclosure scheme for pharmaceutical payments to doctors excludes non-Medicines New Zealand members and omits certain payment types.

New Zealand's new disclosure scheme for pharmaceutical payments to doctors has been deemed to fall short of best practice. Though a welcome development given the absence of relevant legislation, the scheme only includes members of Medicines New Zealand, representing less than half the pharmaceutical companies operating in the country. Some member companies did not participate and several payment types, including hospitality, conference sponsorship, and research funding, were omitted.

March 14, 2024
6 Articles

Further Reading